NEW YORK – Spotlight Medical on Friday said it has raised €6.2 million ($6.7 million) in a seed funding round led by Kurma Partners and Heal Capital.
Paris-based Spotlight is developing artificial intelligence-powered clinical tests that analyze biological information from patient data and predict treatment response. The firm aims to use these tests to reduce over- and under-treatment of cancer patients, improve their outcomes, and reduce treatment side effects. Spotlight will use the raised funds to advance its first AI-based prognostic test to the clinic.
"This investment will accelerate our mission to harness the power of AI in analyzing patient data, providing physicians with the insights they need to make more informed treatment decisions," Spotlight CEO Sylvain Berlemont said in a statement.
Spotlight emerged from stealth mode in June. The AI technology underlying its tests was developed by researchers and clinicians from the Institut Curie cancer research center, the research university Mines Paris – PSL, and Inserm, the national French health and medical research institute. The company has said that its AI technology is "versatile" and can be used to inform treatment in various cancer types, though it has yet to announce the first test indication it will pursue.